Compare ADMA Biologics Inc (ADMA) vs General Dynamics Corporation (GD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs General Dynamics Corporation — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while General Dynamics Corporation trades at $372.8 (market cap $101.31B). The key difference: General Dynamics Corporation is far larger — about 47.6× ADMA Biologics Inc's market cap, and General Dynamics Corporation pays a 1.7% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GD | |
|---|---|---|
Market Cap | $2.13B | $101.31B |
Sector | Health | Industrials |
52-Week High | $20.38 | $376.88 |
52-Week Low | $7.60 | $296.65 |
Enterprise Value | $2.20B | $107.49B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
General Dynamics (GD) trades at $374.64, up 0.29% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, while fundamentals are solid with revenue growth to $52.55 billion in 2025 and net income of $4.21 billion. Recent earnings beats and a massive $130.8 billion backlog support positive momentum, with analyst consensus leaning bullish.
Outlook remains favorable given defense budget tailwinds and execution strength, but valuation multiples like P/E of 23.72 suggest limited upside from current levels. Risks include contract execution delays and macroeconomic pressures. The stock offers steady growth and income via dividends, but investors should weigh rich valuations against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
